MAIA Biotechnology, Inc. (MAIA) is a publicly traded Healthcare sector company. As of May 21, 2026, MAIA trades at $1.29 with a market cap of $76.61M and a P/E ratio of -1.82. MAIA moved +3.66% today. Year to date, MAIA is -14.57%; over the trailing twelve months it is -29.12%. Its 52-week range spans $0.87 to $3.48. Analyst consensus is buy with an average price target of $14.00. Rallies surfaces MAIA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MAIA Biotechnology Raises $30 Million Through 20M-Share Public Offering: MAIA Biotechnology closed a public offering of 20 million common shares at $1.50 per share, raising $30 million in gross proceeds and granting underwriters a 30-day option for an additional 3 million shares. Net proceeds will fund clinical trials, working capital, and general corporate purposes.
| Metric | Value |
|---|---|
| Price | $1.29 |
| Market Cap | $76.61M |
| P/E Ratio | -1.82 |
| EPS | $-0.70 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.48 |
| 52-Week Low | $0.87 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-22.40M |
| Gross Margin | 0.00% |
1 analysts cover MAIA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.00.